BTIG Initiates Coverage On TScan Therapeutics with Buy Rating, Announces Price Target of $12
Portfolio Pulse from Benzinga Newsdesk
BTIG has initiated coverage on TScan Therapeutics (NASDAQ:TCRX) with a Buy rating and set a price target of $12.
May 16, 2024 | 2:12 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
BTIG has initiated coverage on TScan Therapeutics with a Buy rating and set a price target of $12.
The initiation of coverage with a Buy rating and a specific price target of $12 by a reputable analyst can positively influence investor sentiment and potentially drive the stock price up in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100